source
- FDA rejects Summit and Akeso's ivonescimab for narrow lung cancerThe U.S. Food and Drug Administration has turned down ivonescimab, a new cancer therapy being developed by Summit Therapeutics and Akeso, for use in a specific type of lung cancer. Analysts had la…
- Moderna says it is ready to produce thousands of doses of its Merck-partnered cancer vaccine ahead of FDA filingModerna announced that it is on track to manufacture large quantities of a cancer vaccine developed in partnership with Merck. The company says production facilities are prepared to produce thousa…